Evidence map›Paper›PMID 32901384›Full record

ArticlePharmaceutical research2020

Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice.

Tomoki Yoneyama, Sho Sato, Andy Sykes, Rosa Fradley, Stuart Stafford, Shyam Bechar, Eimear Howley, Toshal Patel, Yoshihiko Tagawa, Toshiya Moriwaki and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Pharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. D-Serine: A Cross Species Review of Safety.Frontiers in psychiatry · 2021
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Tomoki YoneyamaDrug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan. tomoki.yoneyama@takeda.com.ORCID http://orcid.org/0000-0002-2207-3505
Sho SatoDrug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
Andy SykesDrug Metabolism and Pharmacokinetics Research Laboratories, Takeda Cambridge Ltd, Cambridge, UK.
Rosa FradleyPharmacology, Takeda Cambridge Ltd, Cambridge, UK.
Stuart StaffordPharmacology, Takeda Cambridge Ltd, Cambridge, UK.
Shyam BecharPharmacology, Takeda Cambridge Ltd, Cambridge, UK.
Eimear HowleyPharmacology, Takeda Cambridge Ltd, Cambridge, UK.
Toshal PatelPharmacology, Takeda Cambridge Ltd, Cambridge, UK.
Yoshihiko TagawaDrug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
Toshiya MoriwakiDrug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
Satoru AsahiDrug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
Takeda (United Kingdom) · GBTakeda (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics (PK), target occupancy (TO) and D-serine concentrations as a pharmacodynamic (PD) readout was established in mice.

methodsPK, TO and PD time-profiles were obtained in mice and analyzed by mechanistic binding kinetics model connected with an indirect response model in a step wise fashion. Brain distribution was investigated to elucidate a possible mechanism driving the hysteresis between PK and TO.

resultsThe observed nonlinear PK/TO/PD relationship was well captured by mechanistic modeling framework within a wide dose range of TAK-831 in mice. Remarkably different brain distribution was observed between target and reference regions, suggesting that the target-mediated slow binding kinetics rather than slow penetration through the blood brain barrier caused the observed distinct kinetics between PK and TO.

conclusionA quantitative mechanistic model for concentration- and time-dependent nonlinear PK/TO/PD relationship was established for TAK-831 in mice with accounting for possible rate-determining process. The established mechanistic modeling framework will provide a quantitative means for multilayer biomarker-assisted clinical development in multiple central nervous system indications.

Indexed as

AnimalsBrainD-Amino-Acid OxidaseDose-Response Relationship, DrugMaleMiceMice, Inbred C57BLPharmacokineticsPharmacologySchizophreniaD-Amino-Acid OxidaseD-amino acid oxidase inhibitorPK/PD, multilayer quantitative modelTAK-831target occupancy

Identifiers

PMID32901384
PMCPMC7478952
OpenAlexW3084933940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.